BACKGROUND AND PURPOSE: Treatment of intermediate and high-risk @entity263 with a high BED has been shown to increase @entity1349 ( @entity1349 ). While @entity1168 ( @entity1168 ) brachytherapy, given as a boost is effective in delivering a high BED, many @entity1 are not candidates for the procedure or wish to avoid an invasive procedure. We evaluated the use of stereotactic body radiotherapy (SBRT) as a boost, with dosimetry modeled after @entity1168 -boost. MATERIAL AND METHODS: Fifty @entity1 were treated with two fractions of SBRT (9.5-10.5  Gy/fraction) after 45  Gy external-beam radiotherapy, with 48 eligible for analysis at a median follow-up of 42.7  months. RESULTS: The Kaplan-Meier estimates of biochemical control post-radiation therapy (95  % Confidence Interval) at 3, 4 and 5  years were 95  % (81-99  %), 90  % (72-97  %) and 90  % (72-97  %), respectively (not counting 2 @entity1 with a PSA bounce as failures). @entity1349 (defined as disease recurrence or @entity204 ) estimates at 3, 4 and 5  years were 92  % (77-97  %), 88  % (69-95  %) and 83  % (62-93  %) if @entity1 with PSA bounces are not counted as failures, and were 90  % (75-96  %), 85  % (67-94  %) and 75  % (53-88  %) if they were. The median time to PSA nadir was 26.2  months (range 5.8-82.9  months), with a median PSA nadir of 0.05  ng/mL (range <0.01-1.99  ng/mL). 2 @entity1 had a "benign PSA bounce", and 4 @entity1 recurred with radiographic evidence of recurrence beyond the RT fields. Treatment was well tolerated with no acute G3 or higher GI or GU @entity137 and only a single G3 late GU @entity137 of @entity1876 . CONCLUSIONS: SBRT boost is well-tolerated for intermediate and high-risk @entity263 @entity1 with good biochemical outcomes and low @entity137 .

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity1876 :: ('MESH:D001748', 'Disease') :: ['urinary obstruction'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1168 :: ('MESH:D001919', 'Disease') :: ['HDR', 'high dose rate'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['recurrence free survival', 'RFS']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
